(Q36148416)

12 August 2017

1 reference

title

Design of effective immunotherapy for human autoimmunity (English)

1 reference

12 August 2017

1 reference

Marc Feldmann

1

1 reference

12 August 2017

Lawrence Steinman

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

435

1 reference

12 August 2017

issue

7042

1 reference

12 August 2017

page(s)

612-619

1 reference

https://scigraph.springernature.com/pub.10.1038/nature03727

12 August 2017

exact match

0 references

cites work

Opinion: Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Immune therapy for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

CD3-specific antibody-induced active tolerance: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

A critical role for OX40 in T cell-mediated immunopathology during lung viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Anti B cell therapy (rituximab) in the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Role of cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Inhibition of IL-6 for the treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Interleukin-15: a new cytokine target for the treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

HMGB1 in the immunology of sepsis (not septic shock) and arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

The concept of specific immune treatment against autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Oral Tolerance in the Treatment of Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Making antibodies by phage display technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Cellular sites of immunologic unresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Engineering better cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Interferon-β in the treatment of relapsing–remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Inactivation of TNF signaling by rationally designed dominant-negative TNF variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Progress in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Rheumatoid arthritis and malignant lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Interleukin-10 inhibition of the progression of established collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

Transplantation 50 years later--progress, challenges, and promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Development of anti-TNF therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Monoclonal antibodies to CD4

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Regulatory/suppressor T cells in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Reflections on chemokines

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Targeting cytokines to inflammation sites

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03727

7 January 2021

Identifiers

DOI

10.1038/NATURE03727

1 reference

Dimensions Publication ID

12 August 2017

1006381650

0 references

1 reference